Loading clinical trials...
Loading clinical trials...
A Phase 2, Placebo-controlled, Adaptive Design Study to Explore the Safety and Efficacy of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) and Possible Other Treatments in Adolescent and Adult Males With Fragile X Syndrome (FXS)
Conditions
Interventions
Sulindac (HLX-0201), dose strength 1
Sulindac (HLX-0201), dose strength 2
+2 more
Locations
10
United States
Children's Hospital Colorado
Aurora, Colorado, United States
University of Miami
Miami, Florida, United States
Emory University School of Medicine
Atlanta, Georgia, United States
Rush University Medical Center & Children's Hospital
Chicago, Illinois, United States
Kennedy Krieger Insitute
Baltimore, Maryland, United States
University of Massachusetts Chan Medical School
Worcester, Massachusetts, United States
Start Date
May 25, 2022
Primary Completion Date
October 19, 2022
Completion Date
October 19, 2022
Last Updated
December 8, 2022
NCT06560242
NCT06139172
NCT05418049
NCT07439510
NCT06957054
NCT06261502
Lead Sponsor
Healx Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions